Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An update from Autonomix Medical, Inc. ( (AMIX) ) is now available.
On August 25, 2025, Autonomix Medical, Inc. entered into a purchase agreement with Lincoln Park Capital Fund, LLC, allowing Lincoln Park to purchase up to $15 million in shares of the company’s common stock. This agreement includes a registration rights agreement for the sale of securities under the Securities Act of 1933. The company retains control over the timing and amount of stock sales, which will be used for working capital and general corporate purposes. The agreement also includes limitations on the percentage of shares Lincoln Park can own and conditions under which purchases can occur, potentially impacting the company’s funding strategy and shareholder equity.
The most recent analyst rating on (AMIX) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Autonomix Medical, Inc. stock, see the AMIX Stock Forecast page.
Spark’s Take on AMIX Stock
According to Spark, TipRanks’ AI Analyst, AMIX is a Underperform.
Autonomix Medical, Inc. struggles with severe financial performance issues due to zero revenue and negative cash flow, despite low debt levels. Technical analysis suggests some short-term momentum, but a longer-term downtrend persists. Valuation is significantly impacted by negative earnings and no dividend yield. Positive trial outcomes present a potential opportunity but are insufficient to offset the substantial financial challenges.
To see Spark’s full report on AMIX stock, click here.
More about Autonomix Medical, Inc.
Average Trading Volume: 1,331,214
Technical Sentiment Signal: Sell
Current Market Cap: $5.25M
For detailed information about AMIX stock, go to TipRanks’ Stock Analysis page.